Search Articles

View query in Help articles search

Search Results (1 to 10 of 17 Results)

Download search results: CSV END BibTex RIS


A Digital Tool for Clinical Evidence–Driven Guideline Development by Studying Properties of Trial Eligible and Ineligible Populations: Development and Usability Study

A Digital Tool for Clinical Evidence–Driven Guideline Development by Studying Properties of Trial Eligible and Ineligible Populations: Development and Usability Study

Such judgments have to be informed by an epidemiological understanding of the clinical population and how it compares to the population studied in RCTs. However, guideline developers are constrained by the lack of tailored epidemiological data analysis designed for this purpose due to data governance, consistency of disease definitions, and reduplicated effort in analysis code.

Shahzad Mumtaz, Megan McMinn, Christian Cole, Chuang Gao, Christopher Hall, Magalie Guignard-Duff, Huayi Huang, David A McAllister, Daniel R Morales, Emily Jefferson, Bruce Guthrie

J Med Internet Res 2025;27:e52385

SARS-CoV-2 Infection Risk by Vaccine Doses and Prior Infections Over 24 Months: ProHEpiC-19 Longitudinal Study

SARS-CoV-2 Infection Risk by Vaccine Doses and Prior Infections Over 24 Months: ProHEpiC-19 Longitudinal Study

To apply these survival models, it is necessary to have a well-characterized cohort of individuals, such as the Professionals’ Health in Epidemiological Crises COVID-19 (Pro HEpi C-19) cohort. This cohort provides a well-characterized population of health care workers (HCWs) to investigate the multiple determinants of risk of new infection [20].

Pere Torán-Monserrat, Noemí Lamonja-Vicente, Anna Costa-Garrido, Lucía A Carrasco-Ribelles, Bibiana Quirant, Marc Boigues, Xaviera Molina, Carla Chacón, Rosalia Dacosta-Aguayo, Fernando Arméstar, Eva María Martínez Cáceres, Julia G Prado, Concepción Violán, ProHEpiC-19 study group

JMIR Public Health Surveill 2024;10:e56926